FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783201861> ?p ?o ?g. }

• W2783201861 endingPage "190" @default.
• W2783201861 startingPage "190" @default.
• W2783201861 abstract "Background: We recently reported the results of the phase III randomized HOVON87/NMSG18 study showing comparable efficacy of treatment with melphalan, prednisolone and thalidomide following by thalidomide maintenance (MPT-T) versus melphalan, prednisolone and lenalidomide followed by lenalidomide maintenance (MPR-R) (Zweegman S et al. Blood 2016;127(9):1109- 1116). As not only efficacy but also potential toxicity affecting quality of life (QoL) guides the choice of treatment, health-related (HR) QoL is important. Aims: To evaluate the HRQoL results of the HOVON87/NMSG18 study. Methods: Two validated HRQoL instruments (EORTC QLQ-C30 and MY20) were obtained at baseline, after 3 and 9 induction cycles (3ID and 9ID) and after 6 and 12 months of maintenance therapy (6MT and 12MT). The subscales global QoL, physical functioning, pain, fatigue, constipation, diarrhea, nausea/vomiting, insomnia, disease symptoms, side effects of treatment and neuropathy were analysed. Change in HRQoL score over time between treatment arms was assessed by linear mixed models. Independent sample t-tests were used to determine changes from baseline. Minimal important difference (MID) within arms was defined as a difference in score of >=1 standard error of measurement (SEM) or, if a subscale consisted of one parameter only, MIDlevels described in previous literature were used. To determine clinically relevant superiority of one arm, a difference in score of >=5 was used and in addition significance level was calculated. Results: From 553 (90.2%) of the 613 patients who participated in the HRQoL part of the study a baseline questionnaire was available. Forty (15%) of patients randomized to MPT-T versus 68 (24%) of patients randomized to MPR-R completed therapy until 12 months of maintenance therapy. Change in HRQoL between arms over time: in MPT-T improvement of HRQoL over time as compared to MPR-R was found for the subscales diarrhea and insomnia. In contrast, MPR-R showed improvement over time for the subscales pain, constipation, side effects of treatment and neuropathy, as compared to MPT-T. Change in HRQoL per arm: In MPT-T MID was reached for the following subscales; global QoL increased after 9ID until 12MT (MID range 7-13), pain decreased at every time point (MID range -21 to -23), disease symptoms deceased after 9ID (MID -12), fatigue decreased during MT (MID 12) and insomnia decreased at each time point (MID range -11 to -21). In MPR-R the MID was reached for the following subscales; global QoL increased after 9ID until 12MT (MID range 8-14), physical functioning increased at 12MT (MID 13), pain decreased at every time point (MID range -14 to -26) and insomnia decreased at 6MT (MID -10). Difference between MPT-T and MPR-R: In the MPT-T arm significantly (p=5 points) less pain and disease symptoms at 3ID, less fatigue at 3ID and 9ID, less diarrhea and less insomnia at all time points were observed. In contrast, patients on MPRR reported better global QoL, better physical functioning and less pain at 12MT, in general less side effects of treatment, and less constipation and neuropathy separately, at all time points than patients treated with MPT-T. (Table Presented) Summary/Conclusions: Both treatment with MPT-T and MPR-R controlled pain and resulted in an improvement in global QoL as compared to baseline after 9ID and during maintenance. Treatment with thalidomide initially resulted in less pain and disease symptoms. At all treatment stages thalidomide caused less diarrhea, fatigue and insomnia as compared to treatment with lenalidomide. In contrast, therapy with lenalidomide resulted in less side effects of treatment, less constipation and less neuropathy as compared to thalidomide at all stages of treatment. In addition, long term maintenance therapy with lenalidomide resulted in better global QoL, better physical functioning and less pain." @default.
• W2783201861 created "2018-01-26" @default.
• W2783201861 creator A5002972322 @default.
• W2783201861 creator A5003689547 @default.
• W2783201861 creator A5004217461 @default.
• W2783201861 creator A5009281777 @default.
• W2783201861 creator A5012101669 @default.
• W2783201861 creator A5013619038 @default.
• W2783201861 creator A5024873802 @default.
• W2783201861 creator A5028707750 @default.
• W2783201861 creator A5032533952 @default.
• W2783201861 creator A5032547644 @default.
• W2783201861 creator A5033356638 @default.
• W2783201861 creator A5033536664 @default.
• W2783201861 creator A5035259712 @default.
• W2783201861 creator A5047262318 @default.
• W2783201861 creator A5049523235 @default.
• W2783201861 creator A5051008993 @default.
• W2783201861 creator A5052113342 @default.
• W2783201861 creator A5056550523 @default.
• W2783201861 creator A5060699933 @default.
• W2783201861 creator A5064088964 @default.
• W2783201861 creator A5070319781 @default.
• W2783201861 creator A5070476948 @default.
• W2783201861 creator A5070900615 @default.
• W2783201861 creator A5071745771 @default.
• W2783201861 creator A5073911102 @default.
• W2783201861 creator A5074443365 @default.
• W2783201861 creator A5074686448 @default.
• W2783201861 creator A5075610619 @default.
• W2783201861 creator A5078774291 @default.
• W2783201861 creator A5080019543 @default.
• W2783201861 creator A5082157943 @default.
• W2783201861 creator A5083385949 @default.
• W2783201861 creator A5089457655 @default.
• W2783201861 date "2017-06-26" @default.
• W2783201861 modified "2023-10-01" @default.
• W2783201861 title "Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma; Results of the Hovon87/NMSG18 study" @default.
• W2783201861 hasPublicationYear "2017" @default.
• W2783201861 type Work @default.
• W2783201861 sameAs 2783201861 @default.
• W2783201861 citedByCount "0" @default.
• W2783201861 crossrefType "journal-article" @default.
• W2783201861 hasAuthorship W2783201861A5002972322 @default.
• W2783201861 hasAuthorship W2783201861A5003689547 @default.
• W2783201861 hasAuthorship W2783201861A5004217461 @default.
• W2783201861 hasAuthorship W2783201861A5009281777 @default.
• W2783201861 hasAuthorship W2783201861A5012101669 @default.
• W2783201861 hasAuthorship W2783201861A5013619038 @default.
• W2783201861 hasAuthorship W2783201861A5024873802 @default.
• W2783201861 hasAuthorship W2783201861A5028707750 @default.
• W2783201861 hasAuthorship W2783201861A5032533952 @default.
• W2783201861 hasAuthorship W2783201861A5032547644 @default.
• W2783201861 hasAuthorship W2783201861A5033356638 @default.
• W2783201861 hasAuthorship W2783201861A5033536664 @default.
• W2783201861 hasAuthorship W2783201861A5035259712 @default.
• W2783201861 hasAuthorship W2783201861A5047262318 @default.
• W2783201861 hasAuthorship W2783201861A5049523235 @default.
• W2783201861 hasAuthorship W2783201861A5051008993 @default.
• W2783201861 hasAuthorship W2783201861A5052113342 @default.
• W2783201861 hasAuthorship W2783201861A5056550523 @default.
• W2783201861 hasAuthorship W2783201861A5060699933 @default.
• W2783201861 hasAuthorship W2783201861A5064088964 @default.
• W2783201861 hasAuthorship W2783201861A5070319781 @default.
• W2783201861 hasAuthorship W2783201861A5070476948 @default.
• W2783201861 hasAuthorship W2783201861A5070900615 @default.
• W2783201861 hasAuthorship W2783201861A5071745771 @default.
• W2783201861 hasAuthorship W2783201861A5073911102 @default.
• W2783201861 hasAuthorship W2783201861A5074443365 @default.
• W2783201861 hasAuthorship W2783201861A5074686448 @default.
• W2783201861 hasAuthorship W2783201861A5075610619 @default.
• W2783201861 hasAuthorship W2783201861A5078774291 @default.
• W2783201861 hasAuthorship W2783201861A5080019543 @default.
• W2783201861 hasAuthorship W2783201861A5082157943 @default.
• W2783201861 hasAuthorship W2783201861A5083385949 @default.
• W2783201861 hasAuthorship W2783201861A5089457655 @default.
• W2783201861 hasConcept C126322002 @default.
• W2783201861 hasConcept C141071460 @default.
• W2783201861 hasConcept C159110408 @default.
• W2783201861 hasConcept C1862650 @default.
• W2783201861 hasConcept C2776063141 @default.
• W2783201861 hasConcept C2776364478 @default.
• W2783201861 hasConcept C2778684742 @default.
• W2783201861 hasConcept C2779609412 @default.
• W2783201861 hasConcept C2779951463 @default.
• W2783201861 hasConcept C2780580376 @default.
• W2783201861 hasConcept C71924100 @default.
• W2783201861 hasConceptScore W2783201861C126322002 @default.
• W2783201861 hasConceptScore W2783201861C141071460 @default.
• W2783201861 hasConceptScore W2783201861C159110408 @default.
• W2783201861 hasConceptScore W2783201861C1862650 @default.
• W2783201861 hasConceptScore W2783201861C2776063141 @default.
• W2783201861 hasConceptScore W2783201861C2776364478 @default.
• W2783201861 hasConceptScore W2783201861C2778684742 @default.
• W2783201861 hasConceptScore W2783201861C2779609412 @default.
• W2783201861 hasConceptScore W2783201861C2779951463 @default.
• W2783201861 hasConceptScore W2783201861C2780580376 @default.
• W2783201861 hasConceptScore W2783201861C71924100 @default.

• next